Literature DB >> 205835

[Diffuse polymorphous inclusions in a patient treated with perhexiline maleate (author's transl)].

J J Hauw, B Singer, R Poupon, D Lecomte, P P de Saint-Maur, A Lageron, S Pollet.   

Abstract

Case report of polyneuritis and liver dysfunction induced by perhexiline maleate in a 64 years old male patient. The ultrastructural study of nerve, liver, muscle and skin biopsies shows polymorphous, membrane bound, often multilamellar, lysosome-like inclusions, the content of which is probably complex lipids. The histochemical study of liver reveals a lipid storage, consisting mainly of triglycerides and of smaller amount of phospholipids and free fatty acids, the pattern of which is abnormal. The biochemical study of nerve tissue shows a decrease of phospholipids levels and some qualitative disturbances in gangliosides. These changes, some of which are similar to those reported in amphiphilic drug intoxications, are prevalent in high lipid metabolism cells such as hepatic and Schwann cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205835

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  4 in total

1.  Effects of Pexid on liver cell cultures. Ultrastructural and histoenzymological studies.

Authors:  A Lageron; J Scotto; M Gautier
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Perhexiline maleate toxicity on human liver cell lines.

Authors:  J Y Le Gall; A Guillouzo; D Glaise; Y Deugnier; M Messner; M Bourel
Journal:  Gut       Date:  1980-11       Impact factor: 23.059

3.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Authors:  M Y Morgan; R Reshef; R R Shah; N S Oates; R L Smith; S Sherlock
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

4.  Lipid and lysosomal enzymes in human fibroblasts cultured with perhexiline maleate.

Authors:  S Albouz; J M Boutry; G Dubois; R Bourdon; J J Hauw; N Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.